http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 26 Aug 2026 17:07:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ESTABLISHMENT+LABS+HOLDI++For%3A+Aug+20++Filed+by%3A+Caldini+Filippo/26982743.html si-local-file:///var/storage/secattach/20260826/26982743.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ESTABLISHMENT+LABS+HOLDI++For%3A+Aug+20++Filed+by%3A+Caldini+Filippo/26982743.html Wed, 26 Aug 2026 17:07:00 -0400 ESTA O.31243832 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ESTABLISHMENT+LABS+HOLDI++For%3A+Aug+20++Filed+by%3A+Caldini+Filippo/26982743.html si-local-file:///var/storage/secattach/20260826/26982743.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ESTABLISHMENT+LABS+HOLDI++For%3A+Aug+20++Filed+by%3A+Caldini+Filippo/26982743.html Wed, 26 Aug 2026 17:07:00 -0400 ESTA O.31243832 http://www.streetinsider.com/Upgrades/Citi+upgrades+Establishment+Labs+to+Buy+with+%2492+target/26915271.html (Updated - August 13, 2026 6:34 AM EDT) <p>Citi analyst Joanne Wuensch upgraded Establishment Labs Inc. (NASDAQ: ESTA) from Neutral to Buy, maintaining a price target of $92.00, according to a research note.</p><p>The upgrade follows a quarter in which ESTA shares fell 13.4% despite reporting total revenue of $67.5M, up 31.7% year-over-year excluding foreign exchange, which exceeded FactSet consensus of $65.8M. U.S. sales reached $24.7M, up approximately 140% year-over-year, while international sales came in at $42.8M, up 4.4%.</p><p>The company reported an EPS loss of $0.39, wider than the consensus estimate of a $0.34 loss. Establishment Labs raised its 2026 revenue guidance http://www.streetinsider.com/Upgrades/Citi+upgrades+Establishment+Labs+to+Buy+with+%2492+target/26915271.html Thu, 13 Aug 2026 06:34:36 -0400 ESTA http://www.streetinsider.com/Hot+Upgrades/Citi+upgrades+Establishment+Labs+to+Buy+with+%2492+target/26915271.html (Updated - August 13, 2026 6:34 AM EDT) <p>Citi analyst Joanne Wuensch upgraded Establishment Labs Inc. (NASDAQ: ESTA) from Neutral to Buy, maintaining a price target of $92.00, according to a research note.</p><p>The upgrade follows a quarter in which ESTA shares fell 13.4% despite reporting total revenue of $67.5M, up 31.7% year-over-year excluding foreign exchange, which exceeded FactSet consensus of $65.8M. U.S. sales reached $24.7M, up approximately 140% year-over-year, while international sales came in at $42.8M, up 4.4%.</p><p>The company reported an EPS loss of $0.39, wider than the consensus estimate of a $0.34 loss. Establishment Labs raised its 2026 revenue guidance http://www.streetinsider.com/Hot+Upgrades/Citi+upgrades+Establishment+Labs+to+Buy+with+%2492+target/26915271.html Thu, 13 Aug 2026 06:34:36 -0400 ESTA http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ESTABLISHMENT+LABS+HOLDI++For%3A+Jun+30/26891025.html si-local-file:///var/storage/secattach/20260807/26891025.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ESTABLISHMENT+LABS+HOLDI++For%3A+Jun+30/26891025.html Fri, 07 Aug 2026 16:07:00 -0400 ESTA O.31243832 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ESTABLISHMENT+LABS+HOLDI++For%3A+Jun+30/26891025.html si-local-file:///var/storage/secattach/20260807/26891025.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ESTABLISHMENT+LABS+HOLDI++For%3A+Jun+30/26891025.html Fri, 07 Aug 2026 16:07:00 -0400 ESTA O.31243832 http://www.streetinsider.com/Analyst+PT+Change/Establishment+Labs+Inc.+%28ESTA%29+PT+Raised+to+%2495+at+JPMorgan/26888322.html JPMorgan analyst Allen Gong raised the price target on Establishment Labs Inc. (NASDAQ: ESTA) to $95.00 (from $84.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Establishment+Labs+Inc.+%28ESTA%29+PT+Raised+to+%2495+at+JPMorgan/26888322.html Fri, 07 Aug 2026 09:03:04 -0400 ESTA http://www.streetinsider.com/Analyst+PT+Change/Establishment+Labs+Inc.+%28ESTA%29+PT+Raised+to+%2495+at+Needham/26883193.html (Updated - August 6, 2026 3:59 PM EDT) <p>Needham analyst Mike Matson raised the price target on Establishment Labs Inc. (NASDAQ: ESTA) to $95.00 (from $86.00) while maintaining a Buy rating.</p><p>The analyst commented: "ESTA's 2Q26 revenue and adjusted EBITDA beat consensus and management raised their 2026 revenue guidance. Revenue growth slowed to 32% in 2Q26 from 45% in 1Q26 and US sales grew 26% sequentially and beat consensus. ESTA's gross margin increased by 190 bps Y/Y and its adjusted EBITDA margin increased by 2,210 bps Y/Y. Mia and Preservé revenue grew 33% sequentially to $12M, demonstrating strong demand in minimally invasive http://www.streetinsider.com/Analyst+PT+Change/Establishment+Labs+Inc.+%28ESTA%29+PT+Raised+to+%2495+at+Needham/26883193.html Thu, 06 Aug 2026 15:59:02 -0400 ESTA http://www.streetinsider.com/Analyst+Comments/Establishment+Labs+Inc.+%28ESTA%29+PT+Raised+to+%2495+at+Needham/26883193.html (Updated - August 6, 2026 3:59 PM EDT) <p>Needham analyst Mike Matson raised the price target on Establishment Labs Inc. (NASDAQ: ESTA) to $95.00 (from $86.00) while maintaining a Buy rating.</p><p>The analyst commented: "ESTA's 2Q26 revenue and adjusted EBITDA beat consensus and management raised their 2026 revenue guidance. Revenue growth slowed to 32% in 2Q26 from 45% in 1Q26 and US sales grew 26% sequentially and beat consensus. ESTA's gross margin increased by 190 bps Y/Y and its adjusted EBITDA margin increased by 2,210 bps Y/Y. Mia and Preservé revenue grew 33% sequentially to $12M, demonstrating strong demand in minimally invasive http://www.streetinsider.com/Analyst+Comments/Establishment+Labs+Inc.+%28ESTA%29+PT+Raised+to+%2495+at+Needham/26883193.html Thu, 06 Aug 2026 15:59:02 -0400 ESTA http://www.streetinsider.com/Analyst+PT+Change/Establishment+Labs+Inc.+%28ESTA%29+PT+Raised+to+%24105+at+Canaccord/26882626.html (Updated - August 6, 2026 2:18 PM EDT) <p>Canaccord analyst Caitlin Cronin raised the price target on Establishment Labs Inc. (NASDAQ: ESTA) to $105.00 (from $90.00) while maintaining a Buy rating.</p><p>The analyst commented: "Bottom Line: ESTA posted a strong quarter driven by US results with revenue and adj. EBITDA exceeding expectations as well as a top line guidance raise. In the US, ESTA exceeded our expectations with sequential growth nearly 15% and Y/Y growth of 140% as the Preservé and broader US launch continues to progress. OUS growth was more modest at 4% Y/Y as ESTA continues to see stabilization in http://www.streetinsider.com/Analyst+PT+Change/Establishment+Labs+Inc.+%28ESTA%29+PT+Raised+to+%24105+at+Canaccord/26882626.html Thu, 06 Aug 2026 14:18:42 -0400 ESTA http://www.streetinsider.com/Analyst+Comments/Establishment+Labs+Inc.+%28ESTA%29+PT+Raised+to+%24105+at+Canaccord/26882626.html (Updated - August 6, 2026 2:18 PM EDT) <p>Canaccord analyst Caitlin Cronin raised the price target on Establishment Labs Inc. (NASDAQ: ESTA) to $105.00 (from $90.00) while maintaining a Buy rating.</p><p>The analyst commented: "Bottom Line: ESTA posted a strong quarter driven by US results with revenue and adj. EBITDA exceeding expectations as well as a top line guidance raise. In the US, ESTA exceeded our expectations with sequential growth nearly 15% and Y/Y growth of 140% as the Preservé and broader US launch continues to progress. OUS growth was more modest at 4% Y/Y as ESTA continues to see stabilization in http://www.streetinsider.com/Analyst+Comments/Establishment+Labs+Inc.+%28ESTA%29+PT+Raised+to+%24105+at+Canaccord/26882626.html Thu, 06 Aug 2026 14:18:42 -0400 ESTA http://www.streetinsider.com/Earnings/Establishment+Labs+Holdings+%28ESTA%29+Misses+Q2+EPS+by+5c/26879631.html <p>Establishment Labs Holdings (NASDAQ: ESTA) reported Q2 EPS of ($0.39), $0.05 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $67.5 million versus the consensus estimate of $65.77 million.</p><p>For earnings history and earnings-related data on Establishment Labs Holdings (ESTA) <a href="http://www.streetinsider.com/ec_earnings.php?q=ESTA">click here</a>.</p> http://www.streetinsider.com/Earnings/Establishment+Labs+Holdings+%28ESTA%29+Misses+Q2+EPS+by+5c/26879631.html Thu, 06 Aug 2026 08:29:15 -0400 ESTA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ESTABLISHMENT+LABS+HOLDI++For%3A+Aug+06/26879359.html si-local-file:///var/storage/secattach/20260806/26879359.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ESTABLISHMENT+LABS+HOLDI++For%3A+Aug+06/26879359.html Thu, 06 Aug 2026 08:05:00 -0400 ESTA O.31243832 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ESTABLISHMENT+LABS+HOLDI++For%3A+Aug+06/26879359.html si-local-file:///var/storage/secattach/20260806/26879359.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ESTABLISHMENT+LABS+HOLDI++For%3A+Aug+06/26879359.html Thu, 06 Aug 2026 08:05:00 -0400 ESTA O.31243832 http://www.streetinsider.com/Press+Releases/Establishment+Labs%C2%AE+Reports+Second+Quarter+2026+Financial+Results/26879180.html <p> NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2026. </p><p> <b><span class="bwuline">Second Quarter Highlights and Outlook (Unaudited)</span></b> </p><ul class="bwlistdisc"> <li> Revenue of $67.5 million, up 31.7% from Q2 2025, and sequential growth of 12.8% from Q1 2026 </li> <li> $24.7 million of sales in the United States, up 26% from Q1 2026 </li> <li> Guidance raised to $269 million to $271 million, an increase from previous guidance of $266.5 million to $268.5 million </li> <li> Minimally invasive revenue of $12.1 million http://www.streetinsider.com/Press+Releases/Establishment+Labs%C2%AE+Reports+Second+Quarter+2026+Financial+Results/26879180.html Thu, 06 Aug 2026 08:00:00 -0400 ESTA O.31243832